Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$860 Mln
P/E Ratio
--
P/B Ratio
0.99
Industry P/E
--
Debt to Equity
0.24
ROE
-0.54 %
ROCE
-46.18 %
Div. Yield
0 %
Book Value
8.81
EPS
-5.24
CFO
$-1,201.23 Mln
EBITDA
$-1,640.01 Mln
Net Profit
$-1,660.61 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Intellia Therapeutics (NTLA)
| -26.24 | 6.57 | -14.09 | -58.57 | -44.49 | -9.04 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Intellia Therapeutics (NTLA)
| -61.46 | -12.61 | -70.49 | 117.35 | 270.82 | 7.47 | -28.85 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.65 | 10,315.11 | 21.27 | 23.13 | |
| 301.64 | 8,705.27 | 22.77 | 66.44 | |
| 27.74 | 10,589.59 | -- | -28.77 | |
| 108.51 | 10,559.67 | 32.44 | 14.16 |
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of... transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: 40 Erie Street, Cambridge, MA, United States, 02139 Read more
President, CEO & Director
Dr. John M. Leonard M.D.
President, CEO & Director
Dr. John M. Leonard M.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Intellia Therapeutics Inc (NTLA) stood at $ 1,191 Mln as on 31-Dec-24
The share price of Intellia Therapeutics Inc (NTLA) is $8.60 (NASDAQ) as of 29-Apr-2025 11:44 EDT. Intellia Therapeutics Inc (NTLA) has given a return of -44.49% in the last 3 years.
Intellia Therapeutics Inc (NTLA) has a market capitalisation of $ 860 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Intellia Therapeutics Inc (NTLA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Intellia Therapeutics Inc (NTLA) and enter the required number of quantities and click on buy to purchase the shares of Intellia Therapeutics Inc (NTLA).
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: 40 Erie Street, Cambridge, MA, United States, 02139
The CEO & director of Dr. John M. Leonard M.D.. is Intellia Therapeutics Inc (NTLA), and CFO & Sr. VP is Dr. John M. Leonard M.D..
There is no promoter pledging in Intellia Therapeutics Inc (NTLA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Intellia Therapeutics Inc. (NTLA) | Ratios |
|---|---|
|
Return on equity(%)
|
-54
|
|
Operating margin(%)
|
-923.1
|
|
Net Margin(%)
|
-896.77
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Intellia Therapeutics Inc (NTLA) was $0 Mln.
$0.12
(
